| Literature DB >> 23526567 |
Alexandre Bisdorff1, Gilles Bosser, René Gueguen, Philippe Perrin.
Abstract
Vertigo, dizziness, and unsteadiness (VDU) are common symptoms traditionally considered to result from different kinds of vestibular and non-vestibular dysfunctions. The epidemiology of each symptom and how they relate to each other and to migraine, agoraphobia, motion sickness susceptibility (MSS), vaso-vagal episodes (VVE), and anxiety-depression was the object of this population-based study in north-eastern France. A self-administered questionnaire was returned by 2987 adults (age span 18-86 years, 1471 women). The 1-year prevalence for vertigo was 48.3%, for unsteadiness 39.1%, and for dizziness 35.6%. The three symptoms were correlated with each other, occurred mostly (69.4%) in various combinations rather than in isolation, less than once per month, and 90% of episodes lasted ≤2 min. The three symptoms were similar in terms of female predominance, temporary profile of the episodes, and their link to falls and nausea. Symptom episodes of >1 h increase the risk of falls. VDU are much more common than the known prevalence of vestibular disorders. The number of drugs taken increase VDU even when controlling for age. Each VDU symptom was correlated with each co-morbidity in Chi-squared tests. The data suggest that the three symptoms are more likely to represent a spectrum resulting from a range of similar - rather than from different, unrelated - mechanisms or disorders. Logistic regressions controlling for each vestibular symptom showed that vertigo correlated with each co-morbidity but dizziness and unsteadiness did not, suggesting that vertigo is certainly not a more specific symptom than the other two. A logistic regression using a composite score of VDU, controlling for each co-morbidity showed a correlation of VDU to migraine and VVE but not to MSS and not to agoraphobia in men, only in women.Entities:
Keywords: agoraphobia; anxiety; dizziness; epidemiology; migraine; motion sickness; vaso-vagal; vertigo
Year: 2013 PMID: 23526567 PMCID: PMC3605504 DOI: 10.3389/fneur.2013.00029
Source DB: PubMed Journal: Front Neurol ISSN: 1664-2295 Impact factor: 4.003
One-year prevalence (%) of VDU symptoms according to duration and frequency.
| Frequency | <2 min | 2–20 min | 20 min–1 h | Hours | >12 h | |
|---|---|---|---|---|---|---|
| 1–3/year | Vertigo | 25.98* | 3.26* | 1.52 | 1.58 | 1.17 |
| Dizziness | 19.44 | 2.59 | 1.25 | 1.29 | 0.97 | |
| Unsteadiness | 22.71 | 2.20 | 1.35 | 1.19 | 1.03 | |
| 4–12/year | Vertigo | 14.21* | 0.92 | 0.66 | 0.61 | 0.14 |
| Dizziness | 10.18 | 1.32 | 0.44 | 0.23 | 0.22 | |
| Unsteadiness | 9.89 | 1.19 | 0.53 | 0.4 | 0.21 | |
| >1/month | Vertigo | 4.42* | 0.67 | 0.31 | 0.12 | 0.09 |
| Dizziness | 2.41 | 0.77 | 0.25 | 0.14 | 0.08 | |
| Unsteadiness | 2.94 | 0.61 | 0.29 | 0.20 | 0.15 | |
| >1/week | Vertigo | 1.71 | 0.18 | 0.10 | 0.14 | 0.06 |
| Dizziness | 1.03 | 0.24 | 0.13 | 0.11 | 0.00 | |
| Unsteadiness | 1.28 | 0.25 | 0.10 | 0.04 | 0.05 |
Some participants had short as well as long lasting symptoms, therefore the sums for each symptom are higher than the global prevalence indicated in the text. (*Vertigo more prevalent .
Figure 1The .
The prevalence of combinations of VDU and balance-related fallers, severe unsteadiness, and nausea.
| Fallers (%/Group) | Severe unsteadiness (%/Group) | Nausea | ||||
|---|---|---|---|---|---|---|
| No sympt | 49.6 | 31.7 | 40.8 | 1.2 | 1.1 | 20.5 |
| Vert only | 9 | 11.8 | 10.4 | 2.0 | 2.9* | 45.3* |
| Dizz only | 3.5 | 2.6 | 3.1 | 0.9 | 1.1 | 46.0* |
| Vert + dizz | 5.6 | 7.6 | 6.6 | 3.7 | 4.7* | 51.3* |
| Unstead only | 4.6 | 4.7 | 4.6 | 4.4 | 5.7* | 48.0* |
| Unstead + vert | 8 | 9.3 | 8.6 | 11.4* | 11.9* | 52.1* |
| Unstead + dizz | 3.6 | 2.8 | 3.2 | 14.1* | 17.3* | 65.5* |
| Vert + dizz + unstead | 16.1 | 29.6 | 22.7 | 16.4* | 22.3* | 68.1* |
Vert, vertigo; dizz, dizziness; unstead, unsteadiness. (*.
Percentages per age group and gender comparison for VDUshort, VDUacute, falls, and severe unsteadiness.
| Age groups (years) | VDUshort | VDUacute | Fallers | Severe unsteadiness | ||||
|---|---|---|---|---|---|---|---|---|
| M/F (%) | M/F (%) | M/F (%) | M/F (%) | |||||
| 19–29 | 21/31 | <0.01 | 4/12 | <0.01 | 5/11 | <0.05 | 5/13 | <0.02 |
| 30–39 | 12/33 | <0.01 | 4/12 | <0.01 | 6/8 | ns | 6/10 | <0.01 |
| 40–49 | 15/29 | <0.01 | 3/5 | ns | 4/7 | ns | 3/11 | <0.01 |
| 50–59 | 14/34 | <0.01 | 2/12 | <0.01 | 6/8 | ns | 6/12 | <0.01 |
| 60–69 | 14/21 | <0.01 | 4/8 | ns | 4/8 | <0.01 | 6/9 | ns |
| ≥70 | 17/17 | ns | 7/12 | ns | 3/8 | ns | 5/7 | ns |
Number of drugs, age, and VDU.
| Age groups | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 436 | 538 | 587 | 558 | 632 | 220 | 2971 | ||||
| Number of drugs | 18–29 years (%) | 30–39 years (%) | 40–49 years (%) | 50–59 years % | 60–69 years % | ≥70 years % | Total % | VDUshort % (OR) | VDUacute % (OR) | Falls % (OR) |
| 0 | 85.6 | 74.3 | 72.1 | 46.8 | 25.8 | 11.8 | 55.4 | 18.5 (1) | 4 (1) | 5.1 (1) |
| 1 | 8.9 | 16.4 | 14.8 | 22.0 | 16.9 | 11.8 | 14.7 | 24.6 (1.58) | 9.5 (2.78) | 9.8 (2.2) |
| 2 | 3.4 | 4.3 | 5.3 | 18.1 | 13.1 | 26.4 | 10.3 | 23.8 (1.85) | 6.3 (2.13) | 5.3 (1.3) ns |
| 3 | 1.4 | 3.3 | 1.9 | 8.1 | 16.5 | 15.0 | 7.3 | 15.9 (1.18) ns | 5.6 (2.02) | 6.6 (1.7) ns |
| 4 | 0.2 | 1.1 | 1.9 | 5.7 | 11.1 | 8.2 | 4.6 | 28.1 (2.72) | 7.9 (3.43) | 3.6 (1.0) ns |
| 5 | 0 | 0.2 | 2.0 | 3.0 | 7.1 | 9.1 | 3.2 | 27.7 (2.74) | 15.6 (7.80) | 13.2 (4.1) |
| ≥6 | 0.5 | 0.4 | 1.9 | 3.2 | 9.5 | 17.7 | 4.4 | 40.2 (4.95) | 19.8 (9.35) | 12.3 (3.8) |
| VDUshort (OR) | 1 | 0.77 ns | 0.68 | 0.65 | 0.33 | 0.27 | ||||
| VDUacute (OR) | 1 | 0.84 ns | 0.35 | 0.45 | 0.26 | 0.38 | ||||
The two columns on the right display the % and OR for VDUshort, VDUacute, and balance-related falls adjusted for age, gender, and number of drugs, taking zero drug as reference = 1. The two lower rows the OR for age groups adjusted for number of drugs, gender and age, taking group 18–29 as reference = 1; ns = not significant.
Logistic regression for each co-morbidity controlling for gender, age, and each VDU symptom.
| Vertigo | Dizziness | Unsteadiness | |
|---|---|---|---|
| Migraine | 1.11 (1.01–1.22) | 1.36 (1.21–1.52) | 1.14 (1.03–1.26) |
| MSS | 1.18 (1.09–1.26) | ns | ns |
| VVE | 1.31 (1.20–1.43) | 1.18 (1.08–1.29) | ns |
| Agoraphobia | 1.32 (1.22–1.41) | ns | ns |
| AD | 1.22 (1.16–1.34) | 1.23 (1.12–1.36) | ns |
MSS, motion sickness susceptibility; VVE, vaso-vagal episodes; AD, anxiety-depression. (OR 95% CI).
VDU and co-morbidities controlled for gender and anxiety-depression.
The upper part of each cell shows data for non-AD, the lower for AD participants. Data for men under diagonal line and for women above. AD, anxiety-depression; VVE, vaso-vagal episodes; MSS, motion sickness susceptibility; VDUshort, composite score of VDU symptoms ≤ 1 h; VDUacute, composite score of VDU symptoms > 1 h.